文献速递脑血管病神经重症与神经感染

丁苯酞在急性缺血性卒中患者中的疗效与安全性:一项随机临床试验

Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项在中国59家中心开展的多中心、双盲、安慰剂对照、平行随机临床试验纳入1216例接受静脉溶栓和/或血管内治疗的急性缺血性卒中患者,90天随访。丁苯酞组90天良好功能结局比例为56.7%,安慰剂组为44.0%(OR 1.70;95%CI 1.35-2.14;P<.001)。

要点

  • 丁苯酞组90天良好功能结局344例(56.7%),安慰剂组268例(44.0%)(OR 1.70;95%CI 1.35-2.14;P<.001)。
  • 90天内严重不良事件:丁苯酞组61例(10.1%),安慰剂组73例(12.0%)。
  • 入组标准为NIHSS评分4-25分、症状发作6小时内可开始试验药物并接受静脉rt-PA和/或血管内治疗。

核心结论

  • 在接受静脉溶栓和/或血管内治疗的急性缺血性卒中患者中,与安慰剂相比,丁苯酞与90天获得良好功能结局的患者比例更高相关。

研究设计与样本

  • 多中心、双盲、安慰剂对照、平行随机临床试验,在中国59家中心开展,随访90天。
  • 共筛查1236例急性缺血性卒中患者,排除20例拒绝参与或不符合纳入标准者后,入组1216例18岁及以上患者。
  • 入组患者NIHSS评分4-25分,症状发作6小时内可开始试验药物,并接受静脉rt-PA或血管内治疗或静脉rt-PA桥接血管内治疗。
  • 数据收集时间为2018年7月1日至2022年5月22日。
  • 症状发作6小时内按1:1比例随机接受丁苯酞或安慰剂。

主要发现

  • 1216例入组患者中,827例(68.0%)为男性,中位(IQR)年龄为66(56-72)岁。
  • 607例随机分配至丁苯酞组,609例分配至安慰剂组。
  • 90天良好功能结局:丁苯酞组344例(56.7%),安慰剂组268例(44.0%)(OR 1.70;95%CI 1.35-2.14;P<.001)。
  • 90天内严重不良事件:丁苯酞组61例(10.1%),安慰剂组73例(12.0%)。

关键数值与推荐

  • 主要疗效结局为基于90天改良Rankin量表评分的良好结局比例,阈值视基线卒中严重程度取0-2分(量表范围0分[无症状或完全恢复]至6分[死亡])。
  • 90天良好功能结局:丁苯酞组344例(56.7%)vs 安慰剂组268例(44.0%)(OR 1.70;95%CI 1.35-2.14;P<.001)。
  • 90天内严重不良事件:丁苯酞组61例(10.1%)vs 安慰剂组73例(12.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: DL-3-n-butylphthalide (NBP) is a drug for treating acute ischemic stroke and may play a neuroprotective role by acting on multiple active targets. The efficacy of NBP in patients with acute ischemic stroke receiving reperfusion therapy remains unknown. OBJECTIVE: To assess the efficacy and safety of NBP in patients with acute ischemic stroke receiving reperfusion therapy of intravenous thrombolysis and/or endovascular treatment. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled, parallel randomized clinical trial was conducted in 59 centers in China with 90-day follow-up. Of 1236 patients with acute ischemic stroke, 1216 patients 18 years and older diagnosed with acute ischemic stroke with a National Institutes of Health Stroke Scale score ranging from 4 to 25 who could start the trial drug within 6 hours from symptom onset and received either intravenous recombinant tissue plasminogen activator (rt-PA) or endovascular treatment or intravenous rt-PA bridging to endovascular treatment were enrolled, after excluding 20 patients who declined to participate or did not meet eligibility criteria. Data were collected from July 1, 2018, to May 22, 2022. INTERVENTIONS: Within 6 hours after symptom onset, patients were randomized to receive NBP or placebo in a 1:1 ratio. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the proportion of patients with a favorable outcome based on 90-day modified Rankin Scale score (a global stroke disability scale ranging from 0 [no symptoms or completely recovered] to 6 [death]) thresholds of 0 to 2 points, depending on baseline stroke severity. RESULTS: Of 1216 enrolled patients, 827 (68.0%) were men, and the median (IQR) age was 66 (56-72) years. A total of 607 were randomly assigned to the butylphthalide group and 609 to the placebo group. A favorable functional outcome at 90 days occurred in 344 patients (56.7%) in the butylphthalide group and 268 patients (44.0%) in the placebo group (odds ratio, 1.70; 95% CI, 1.35-2.14; P < .001). Serious adverse events within 90 days occurred in 61 patients (10.1%) in the butylphthalide group and 73 patients (12.0%) in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke receiving intravenous thrombolysis and/or endovascular treatment, NBP was associated with a higher proportion of patients achieving a favorable functional outcome at 90 days compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03539445.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wang A, Jia B, Zhang X, et al. Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37358859. doi:10.1001/jamaneurol.2023.1871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。